Advanced Search

Oncology & Hematology Coding Alert

HCPCS:

Q2048, Q2049 Will Shake Up Your Liposomal Doxorubicin HCL Coding This Summer

Published on Fri Apr 13, 2012

CMS won't be using J9001 for Doxil once the change takes place in July. One of the side effects of drug shortages is that coders have to determine which codes to use for replacement drugs. When deciding how to report two substitution drugs properly -- Lipodox and Fusilev -- consider these recent updates from CMS and Noridian Medicare. Prepare to Use Q2049 This Summer A shortage of Doxil has led to the temporary importation of a replacement drug, Lipodox. Both Doxil and Lipodox involve a doxorubicin hydrochloride liposome injection. CMS has announced new HCPCS codes for Lipodox and Doxil. The codes will become effective July 1, 2012, says Kelly Loya, CPC-I, CHC, CPhT, manager for Sinaiko Healthcare Consulting Inc., a reimbursement services division of Altegra Health. As you can see from the new codes' definitions, they distinguish between Doxil and Lipodox: Q2048, Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg Q2049, Injection, doxorubicin [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All